179 related articles for article (PubMed ID: 21532616)
1. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer.
Saji M; Narahara K; McCarty SK; Vasko VV; La Perle KM; Porter K; Jarjoura D; Lu C; Cheng SY; Ringel MD
Oncogene; 2011 Oct; 30(42):4307-15. PubMed ID: 21532616
[TBL] [Abstract][Full Text] [Related]
2. Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model.
Saji M; Kim CS; Wang C; Zhang X; Khanal T; Coombes K; La Perle K; Cheng SY; Tsichlis PN; Ringel MD
Sci Rep; 2020 Oct; 10(1):18316. PubMed ID: 33110146
[TBL] [Abstract][Full Text] [Related]
3. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
5. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
6. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer.
Kim CS; Ying H; Willingham MC; Cheng SY
Carcinogenesis; 2007 May; 28(5):932-9. PubMed ID: 17127711
[TBL] [Abstract][Full Text] [Related]
7. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
[TBL] [Abstract][Full Text] [Related]
8. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
Ying H; Willingham MC; Cheng SY
Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
[TBL] [Abstract][Full Text] [Related]
9. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
[TBL] [Abstract][Full Text] [Related]
10. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
Kim CS; Furuya F; Ying H; Kato Y; Hanover JA; Cheng SY
Endocrinology; 2007 Mar; 148(3):1306-12. PubMed ID: 17170101
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4.
Grottke A; Ewald F; Lange T; Nörz D; Herzberger C; Bach J; Grabinski N; Gräser L; Höppner F; Nashan B; Schumacher U; Jücker M
PLoS One; 2016; 11(1):e0146370. PubMed ID: 26741489
[TBL] [Abstract][Full Text] [Related]
12. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
Kato Y; Ying H; Willingham MC; Cheng SY
Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
[TBL] [Abstract][Full Text] [Related]
13. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor.
Zhao L; Zhu X; Won Park J; Fozzatti L; Willingham M; Cheng SY
Endocrinology; 2012 Oct; 153(10):5090-100. PubMed ID: 22919057
[TBL] [Abstract][Full Text] [Related]
14. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
15. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.
Vasko V; Saji M; Hardy E; Kruhlak M; Larin A; Savchenko V; Miyakawa M; Isozaki O; Murakami H; Tsushima T; Burman KD; De Micco C; Ringel MD
J Med Genet; 2004 Mar; 41(3):161-70. PubMed ID: 14985374
[TBL] [Abstract][Full Text] [Related]
16. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.
Lu C; Zhu X; Willingham MC; Cheng SY
Oncogene; 2012 Apr; 31(16):2007-16. PubMed ID: 21909131
[TBL] [Abstract][Full Text] [Related]
17. The effect Akt2 deletion on tumor development in Pten(+/-) mice.
Xu PZ; Chen ML; Jeon SM; Peng XD; Hay N
Oncogene; 2012 Jan; 31(4):518-26. PubMed ID: 21743498
[TBL] [Abstract][Full Text] [Related]
18. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.
Suzuki H; Willingham MC; Cheng SY
Thyroid; 2002 Nov; 12(11):963-9. PubMed ID: 12490073
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
Fozzatti L; Park JW; Zhao L; Willingham MC; Cheng SY
PLoS One; 2013; 8(6):e67954. PubMed ID: 23840792
[TBL] [Abstract][Full Text] [Related]
20. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.
Riggio M; Perrone MC; Polo ML; Rodriguez MJ; May M; Abba M; Lanari C; Novaro V
Sci Rep; 2017 Mar; 7():44244. PubMed ID: 28287129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
